<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
hero-press-releases-1

Newsroom

Press Releases

Our latest announcements

Posts in: cancer immunotherapy

Society for Advanced Bronchoscopy Commits to Enhance Education and Practice Excellence as U.S. Demand for Bronchoscopy Procedures Increases

Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans

Society for Advanced Bronchoscopy Meets May 20 to Address “Hot Topics in Advanced Bronchoscopy"

The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.

New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions

New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.

Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients

Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

Dr. Jeffrey Weber will present study results of new Biodesix immunotherapy test at ITOC4

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.

Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC

The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision